CO2021006924A2 - Pirazoles como moduladores de la hemoglobina - Google Patents
Pirazoles como moduladores de la hemoglobinaInfo
- Publication number
- CO2021006924A2 CO2021006924A2 CONC2021/0006924A CO2021006924A CO2021006924A2 CO 2021006924 A2 CO2021006924 A2 CO 2021006924A2 CO 2021006924 A CO2021006924 A CO 2021006924A CO 2021006924 A2 CO2021006924 A2 CO 2021006924A2
- Authority
- CO
- Colombia
- Prior art keywords
- modulators
- tautomers
- processes
- pyrazoles
- hemoglobin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La invención se relaciona con derivados de pirazol, con su uso en medicina, con composiciones que los contienen, con procesos para su preparación y con intermediarios utilizados en tales procesos. Más particularmente la invención se relaciona con moduladores de HbS de la Fórmula (I) (I) o tautómeros de los mismos, o sales farmacéuticamente aceptables de los moduladores o tautómeros de los mismos, en donde X, Y, R2 y R3 son como se definen en la descripción. Los moduladores de HbS son potencialmente útiles en el tratamiento de un amplio margen de trastornos, que incluyen enfermedad de células falciformes (SCD).
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862772815P | 2018-11-29 | 2018-11-29 | |
US201962915784P | 2019-10-16 | 2019-10-16 | |
PCT/IB2019/060171 WO2020109994A1 (en) | 2018-11-29 | 2019-11-26 | Pyrazoles as modulators of hemoglobin |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2021006924A2 true CO2021006924A2 (es) | 2021-06-10 |
Family
ID=68807213
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2021/0006924A CO2021006924A2 (es) | 2018-11-29 | 2021-05-26 | Pirazoles como moduladores de la hemoglobina |
Country Status (22)
Country | Link |
---|---|
US (3) | US11014908B2 (es) |
EP (1) | EP3886984A1 (es) |
JP (1) | JP2022510628A (es) |
KR (1) | KR20210097161A (es) |
CN (1) | CN113329789A (es) |
AU (1) | AU2019387290A1 (es) |
BR (1) | BR112021009057A2 (es) |
CA (1) | CA3121139A1 (es) |
CO (1) | CO2021006924A2 (es) |
CR (1) | CR20210284A (es) |
CU (1) | CU20210044A7 (es) |
DO (1) | DOP2021000103A (es) |
EC (1) | ECSP21037191A (es) |
IL (1) | IL283408A (es) |
MA (1) | MA54283A (es) |
MX (1) | MX2021006095A (es) |
PE (1) | PE20211592A1 (es) |
PH (1) | PH12021551035A1 (es) |
SG (1) | SG11202104585YA (es) |
TW (2) | TW202140452A (es) |
UY (1) | UY38488A (es) |
WO (1) | WO2020109994A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2019387290A1 (en) * | 2018-11-29 | 2021-05-27 | Pfizer Inc. | Pyrazoles as modulators of hemoglobin |
MX2022009130A (es) | 2020-01-24 | 2022-08-22 | Pfizer | Anticuerpos anti-e-selectina, composiciones y metodos de uso. |
CN112079774A (zh) * | 2020-10-17 | 2020-12-15 | 甘肃天后光学科技有限公司 | 软性隐形眼镜用蓝光吸收剂、其制备方法及应用方法 |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
US20040167188A1 (en) | 2003-02-14 | 2004-08-26 | Zhili Xin | Protein-tyrosine phosphatase inhibitors and uses thereof |
US7169797B2 (en) | 2003-02-14 | 2007-01-30 | Abbott Laboratories | Protein-tyrosine phosphatase inhibitors and uses thereof |
JP5315611B2 (ja) | 2004-06-23 | 2013-10-16 | 小野薬品工業株式会社 | S1p受容体結合能を有する化合物およびその用途 |
WO2006003923A1 (ja) | 2004-06-30 | 2006-01-12 | Sankyo Company, Limited | 置換ベンゼン化合物 |
JP2007176799A (ja) | 2005-12-27 | 2007-07-12 | Sankyo Co Ltd | 置換ベンゼン化合物を含有する医薬 |
US8039442B2 (en) | 2007-07-18 | 2011-10-18 | Glycomimetics, Inc. | Compounds and methods for treatment of sickle cell disease or complications associated therewith |
WO2011015524A2 (en) | 2009-08-03 | 2011-02-10 | Bayer Cropscience Ag | Fungicide heterocycles derivatives |
CN102206172B (zh) | 2010-03-30 | 2015-02-25 | 中国医学科学院医药生物技术研究所 | 一组取代双芳基化合物及其制备方法和抗病毒应用 |
JP2013525476A (ja) * | 2010-05-04 | 2013-06-20 | ファイザー・インク | Alk阻害剤としての複素環式誘導体 |
EP2616442B8 (en) | 2010-09-14 | 2018-10-17 | Exelixis, Inc. | Inhibitors of pi3k-delta and methods of their use and manufacture |
WO2012129562A2 (en) | 2011-03-24 | 2012-09-27 | The Scripps Research Institute | Compounds and methods for inducing chondrogenesis |
EP2797597B1 (en) * | 2011-12-28 | 2020-02-26 | Global Blood Therapeutics, Inc. | Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation |
SG11201403645VA (en) * | 2011-12-28 | 2014-07-30 | Global Blood Therapeutics Inc | Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation |
EA033555B1 (ru) | 2013-03-15 | 2019-10-31 | Global Blood Therapeutics Inc | Фармацевтические композиции для лечения серповидно-клеточного нарушения |
US8952171B2 (en) | 2013-03-15 | 2015-02-10 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US9604999B2 (en) | 2013-03-15 | 2017-03-28 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US10266551B2 (en) | 2013-03-15 | 2019-04-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
CA2902711C (en) | 2013-03-15 | 2021-07-06 | Global Blood Therapeutics, Inc. | Substituted pyridinyl-6-methoxy-2-hydroxybenzaldehyde derivatives and pharmaceutical compositions thereof useful for the modulation of hemoglobin |
ES2909634T3 (es) | 2013-03-15 | 2022-05-09 | Global Blood Therapeutics Inc | Compuestos y usos de los mismos para la modulación de hemoglobina |
AU2014237340C1 (en) | 2013-03-15 | 2018-11-08 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US9422279B2 (en) | 2013-03-15 | 2016-08-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US20140271591A1 (en) * | 2013-03-15 | 2014-09-18 | Global Blood Therapeutics, Inc. | Compositions and methods for the modulation of hemoglobin (s) |
US9458139B2 (en) * | 2013-03-15 | 2016-10-04 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US9248199B2 (en) * | 2014-01-29 | 2016-02-02 | Global Blood Therapeutics, Inc. | 1:1 adducts of sickle hemoglobin |
WO2015193506A1 (en) | 2014-06-20 | 2015-12-23 | Institut Pasteur Korea | Anti-infective compounds |
WO2016043849A2 (en) | 2014-07-24 | 2016-03-24 | Global Blood Therapeutics, Inc. | Compounds for treating acute respiratory distress syndrome or a negative effect thereof |
WO2016071211A1 (en) | 2014-11-03 | 2016-05-12 | F. Hoffmann-La Roche Ag | Bace1 inhibitors |
CN107428760B (zh) | 2014-11-16 | 2021-04-27 | 阵列生物制药公司 | (s)-n-(5-((r)-2-(2,5-二氟苯基)-吡咯烷-1-基)-吡唑并[1,5-a]嘧啶-3-基)-3-羟基吡咯烷-1-甲酰胺硫酸氢盐的晶型 |
WO2017096230A1 (en) | 2015-12-04 | 2017-06-08 | Global Blood Therapeutics, Inc. | Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
EP3472150A1 (en) | 2016-06-17 | 2019-04-24 | Fronthera U.S. Pharmaceuticals LLC | Hemoglobin modifier compounds and uses thereof |
CA3033752C (en) | 2016-08-15 | 2022-05-31 | Purdue Research Foundation | 4-substituted aminoisoquinoline derivatives |
AU2019387290A1 (en) * | 2018-11-29 | 2021-05-27 | Pfizer Inc. | Pyrazoles as modulators of hemoglobin |
-
2019
- 2019-11-26 AU AU2019387290A patent/AU2019387290A1/en not_active Abandoned
- 2019-11-26 CU CU2021000044A patent/CU20210044A7/es unknown
- 2019-11-26 PE PE2021000762A patent/PE20211592A1/es unknown
- 2019-11-26 WO PCT/IB2019/060171 patent/WO2020109994A1/en active Application Filing
- 2019-11-26 TW TW110125518A patent/TW202140452A/zh unknown
- 2019-11-26 CR CR20210284A patent/CR20210284A/es unknown
- 2019-11-26 TW TW108142940A patent/TWI736037B/zh not_active IP Right Cessation
- 2019-11-26 KR KR1020217020051A patent/KR20210097161A/ko not_active Application Discontinuation
- 2019-11-26 EP EP19816457.6A patent/EP3886984A1/en not_active Withdrawn
- 2019-11-26 MA MA054283A patent/MA54283A/fr unknown
- 2019-11-26 MX MX2021006095A patent/MX2021006095A/es unknown
- 2019-11-26 SG SG11202104585YA patent/SG11202104585YA/en unknown
- 2019-11-26 BR BR112021009057-6A patent/BR112021009057A2/pt not_active Application Discontinuation
- 2019-11-26 CN CN201980090794.6A patent/CN113329789A/zh active Pending
- 2019-11-26 CA CA3121139A patent/CA3121139A1/en not_active Abandoned
- 2019-11-26 US US16/695,709 patent/US11014908B2/en active Active
- 2019-11-26 JP JP2021529740A patent/JP2022510628A/ja active Pending
- 2019-11-27 UY UY0001038488A patent/UY38488A/es unknown
-
2021
- 2021-04-12 US US17/227,819 patent/US11702405B2/en active Active
- 2021-05-05 PH PH12021551035A patent/PH12021551035A1/en unknown
- 2021-05-24 IL IL283408A patent/IL283408A/en unknown
- 2021-05-25 EC ECSENADI202137191A patent/ECSP21037191A/es unknown
- 2021-05-26 DO DO2021000103A patent/DOP2021000103A/es unknown
- 2021-05-26 CO CONC2021/0006924A patent/CO2021006924A2/es unknown
-
2023
- 2023-05-24 US US18/322,844 patent/US20230382892A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
TWI736037B (zh) | 2021-08-11 |
EP3886984A1 (en) | 2021-10-06 |
US20230382892A1 (en) | 2023-11-30 |
CU20210044A7 (es) | 2022-01-13 |
US11702405B2 (en) | 2023-07-18 |
JP2022510628A (ja) | 2022-01-27 |
US20200172512A1 (en) | 2020-06-04 |
KR20210097161A (ko) | 2021-08-06 |
TW202140452A (zh) | 2021-11-01 |
TW202033513A (zh) | 2020-09-16 |
US11014908B2 (en) | 2021-05-25 |
DOP2021000103A (es) | 2021-07-30 |
ECSP21037191A (es) | 2021-06-30 |
UY38488A (es) | 2020-06-30 |
BR112021009057A2 (pt) | 2021-08-10 |
CA3121139A1 (en) | 2020-06-04 |
IL283408A (en) | 2021-07-29 |
SG11202104585YA (en) | 2021-06-29 |
AU2019387290A1 (en) | 2021-05-27 |
CR20210284A (es) | 2021-07-09 |
MX2021006095A (es) | 2021-07-06 |
MA54283A (fr) | 2022-03-09 |
PH12021551035A1 (en) | 2021-12-06 |
US20220348555A1 (en) | 2022-11-03 |
CN113329789A (zh) | 2021-08-31 |
WO2020109994A1 (en) | 2020-06-04 |
PE20211592A1 (es) | 2021-08-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2021006924A2 (es) | Pirazoles como moduladores de la hemoglobina | |
DOP2014000085A (es) | Derivados de (4-fenilimidazol-2-il)etilamina útiles como moduladores de canal de sodio | |
ECSP20053845A (es) | Macrociclos como moduladores del regulador de conductancia transmembrana de la fibrosis quística, composiciones farmacéuticas de estos, su uso en el tratamiento de la fibrosis quística y procesos para elaborarlos | |
ECSP21004787A (es) | Inhibidores de inflamasoma nlrp3 | |
UY33491A (es) | ?Derivados de sulfonamida y sus sales farmacéuticamente aceptables para uso en medicina?. | |
UY33500A (es) | Derivados de acil sulfonamida y sus sales farmacéuticamente aceptables para uso en medicina | |
CL2017000469A1 (es) | Derivados de tetrahidronaftaleno que inhiben la proteina mcl-1 | |
UY33501A (es) | Derivados de acil sulfonamida y sus sales farmacéuticamente aceptables para uso en medicina | |
PE20151437A1 (es) | Moduladores de receptores nmda de espiro-lactama y sus usos | |
ECSP12012042A (es) | Derivados de pirazol como inhibidores de jak | |
CO7160077A2 (es) | Compuestos de pirazol sustituidos como antagonistas de lpar | |
CO2021005509A2 (es) | Derivados de piridinil sulfonamida, composiciones farmacéuticas y usos de estos | |
CL2019002601A1 (es) | Derivados pirazol[1,5-a]pirimidina sustituidos con alicíclicos farmacológicamente activos. | |
CO2023000056A2 (es) | Derivados de amidopirimidona | |
CR20160084A (es) | Derivados de amida como agonistas del receptor del ácido lisofosfatídico | |
CO2022008313A2 (es) | Compuestos químicos | |
CO2021004553A2 (es) | Nuevos derivados amino-pirimidonil-piperidinilo, un proceso para su preparación y composiciones farmacéuticas que los contienen | |
CO2022012884A2 (es) | Compuestos de amino pirimidina fusionados | |
UY38006A (es) | Inhibidores de la quinasa mtor, composiciones farmacéuticas que los contienen, y al uso en terapia de tales compuestos y composiciones | |
CO2021001174A2 (es) | Inhibidores de ckd8/19 | |
ECSP055673A (es) | Derivados de 4-(3,5-dicianofenoxi) pirazol para el uso como moduladores de transcriptasa reversa en el tratamiento del vih | |
CL2018002010A1 (es) | Derivados de indano y su uso en terapias. | |
UY31812A (es) | Derivados de cinolina como inhibidores de csf-1 | |
UY30699A1 (es) | Derivados sustituidos de 4-fenilamino-quinolina-3-carboxamidas, sales farmacéuticamente aceptables, procesos de preparacion, composiciones conteniéndolos y aplicaciones | |
CL2020000439A1 (es) | Sales de un compuesto y sus formas cristalinas. |